Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection
- 24 April 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 28 (7), 999-1005
- https://doi.org/10.1097/qad.0000000000000180
Abstract
Objective: Current guidelines advise to vaccinate every hepatitis B virus (HBV)-susceptible HIV patient against HBV until sufficient antibody titers have been reached. However, in this era of combination antiretroviral therapy (cART), acute HBV infection rarely occurs in patients who lack this immune protection. We analyzed whether HBV-active cART (lamivudine, emtricitabine, tenofovir) might work as a preexposure prophylaxis (PrEP) to explain this effect. Methods: From our HIV cohort at the Onze Lieve Vrouwe Gasthuis hospital (N = 2942), patients were selected retrospectively for negative HBV serology (HBsAg, anti-HBs and anti-HBc-negative) at cohort entry. Men who have sex with men (MSM) with a second HBV serology available were included for analysis. The incidence of anti-HBc conversion was determined and correlated with the use of HBV-active drugs. Kaplan–Meier curves and log-rank tests were used to compare HBV-free survival for MSM. Results: In total, 33 HBV infections occurred in 381 eligible MSM over a median follow-up of 2470 days (interquartile range 1146–3871.5). The incident rate per 100 patient-years of follow-up was 1.10 overall, but differed strongly dependent on the use of HBV-active drugs: 2.85/100 patient-years of follow-up in the absence of HBV-active drugs, 1.36 when only lamivudine was used, and 0.14 in the presence of tenofovir. Furthermore, HBV-free survival rate was significantly higher when HBV-active cART was used, in particular when this HBV-active cART contained tenofovir (log-rank P <0.001). Conclusion: Our findings demonstrate that HBV-active cART protects against the occurrence of de-novo HBV infection, most strongly when tenofovir is used.Keywords
This publication has 15 references indexed in Scilit:
- Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus InfectionClinical Infectious Diseases, 2013
- Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) StudyPLOS ONE, 2012
- Hepatitis B and long-term HIV outcomes in coinfected HAART recipientsAIDS, 2009
- Monotherapy versus combination therapy for the treatment of chronic hepatitis BExpert Opinion on Investigational Drugs, 2009
- Impact of Hepatitis B Virus Infection on the Progression of AIDS and Mortality in HIV‐Infected Individuals: A Cohort Study and Meta‐AnalysisClinical Infectious Diseases, 2009
- Comparisons of Causes of Death and Mortality Rates Among HIV-Infected PersonsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohortAIDS, 2005
- Prevalence of Chronic Hepatitis B and Incidence of Acute Hepatitis B Infection in Human Immunodeficiency Virus–Infected SubjectsThe Journal of Infectious Diseases, 2003
- Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Epidemiology, Natural History, and TreatmentSeminars in Liver Disease, 2003
- Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001